Pathstone Holdings
IKT icon

Pathstone Holdings’s Inhibikase Therapeutics IKT Stock Holding History

Pathstone Holdings’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
+510,596
New +$914K ﹤0.01% 1490

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pathstone Holdings's IKT Position: Q2 2026 in Review

Pathstone Holdings opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 510,596 shares worth $1.04M. The stake represents ﹤0.01% of the portfolio and ranks #1490 among its holdings.

106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Pathstone Holdings held 510,596 shares of Inhibikase Therapeutics worth $1.04M as of Q2 2026.
  • Inhibikase Therapeutics was a new Pathstone Holdings position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1490 holding.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.